• Methodologies
  • HPLC
  • LCMSMS
  • In Development/Validation
  • Other Methods
• Organization
• Personnel
• Equipment
• Projects
• Contact Us
• LogIn

New assays in development:

• darunavir assay, which will include atazanavir, efavirenz, lopinavir, saquinavir, and ritonavir
• nevirapine, lamivudine and stavudine

Tipranavir

The concentration of tipranavir is measured in plasma using a method developed at and validated at the Laboratory for Antiviral Research at the State University of New York at Buffalo. Tipranavir is analyzed by extraction from 250 �L of plasma (EDTA or Na heparin) via a liquid-liquid extraction with ethylene dichloride, followed by centrifugation, aspiration of aqueous layer and evaporation under a nitrogen stream. Samples are reconstituted with mobile phase and injected into the chromatography system. UV detection is used at a wavelength of 248 nm.

The chromatographic system consists of a Waters Model 515 pump, a Waters Model 717plus autosampler, a Waters column heater and temperature control module, and a Waters PDA detector. The chromatographic system is controlled by Waters Empower software, which also collects all chromatographic data generated during analysis. This program was utilized to assess: (1) all chromatographic data for the analysis, (2) generate calibration standard curves and their corresponding statistics, and (3) calculate specimen concentrations.

The method was approved by NYS DOH for use in Therapeutic Drug Monitoring.

Characteristics of the method are as follows: